Podcasts about car t cell

Olá, ouvintes! Neste novo episódio do Abrale Cast, entrevistamos o Dr. Renato Cunha, médico hematologista, pesquisador, líder da terapia celular do Grupo Oncoclínicas e professor da UNIFESP (Universidade Federal de São Paulo). Falamos sobre como as terapias celulares funcionam, além de tópicos como o CAR-T CELL e transplante de medula óssea. Vem conferir!

- Overview of CAR T-Cell Therapies - Understanding CARs – Chimeric Antigen Receptors - When to Consider CAR T-Cell Therapies as a Treatment Choice - Clinical Trials for CAR T-Cell Therapies - Discussion of CAR T-Cell Therapies - Managing Potential Treatment Side Effects - Specific Examples of How CAR T-Cell Therapies Contribute to Oncology Care - Key Questions to Ask Your Health Care Team about CAR T-Cell Therapies - The Benefits of CAR T-Cell Therapies - Follow-Up Care: What to Expect - Guidelines to Prepare for Telehealth/Telemedicine Appointments, Including Technology and List of Questions - Questions for Our Panel of Experts

- Overview of CAR T-Cell Therapies - Understanding CARs – Chimeric Antigen Receptors - When to Consider CAR T-Cell Therapies as a Treatment Choice - Clinical Trials for CAR T-Cell Therapies - Discussion of CAR T-Cell Therapies - Managing Potential Treatment Side Effects - Specific Examples of How CAR T-Cell Therapies Contribute to Oncology Care - Key Questions to Ask Your Health Care Team about CAR T-Cell Therapies - The Benefits of CAR T-Cell Therapies - Follow-Up Care: What to Expect - Guidelines to Prepare for Telehealth/Telemedicine Appointments, Including Technology and List of Questions - Questions for Our Panel of Experts

- Overview of CAR T-Cell Therapies - Understanding CARs – Chimeric Antigen Receptors - When to Consider CAR T-Cell Therapies as a Treatment Choice - Clinical Trials for CAR T-Cell Therapies - Discussion of CAR T-Cell Therapies - Managing Potential Treatment Side Effects - Specific Examples of How CAR T-Cell Therapies Contribute to Oncology Care - Key Questions to Ask Your Health Care Team about CAR T-Cell Therapies - The Benefits of CAR T-Cell Therapies - Follow-Up Care: What to Expect - Guidelines to Prepare for Telehealth/Telemedicine Appointments, Including Technology and List of Questions - Questions for Our Panel of Experts

- Overview of CAR T-Cell Therapies - Understanding CARs – Chimeric Antigen Receptors - When to Consider CAR T-Cell Therapies as a Treatment Choice - Clinical Trials for CAR T-Cell Therapies - Discussion of CAR T-Cell Therapies - Managing Potential Treatment Side Effects - Specific Examples of How CAR T-Cell Therapies Contribute to Oncology Care - Key Questions to Ask Your Health Care Team about CAR T-Cell Therapies - The Benefits of CAR T-Cell Therapies - Follow-Up Care: What to Expect - Guidelines to Prepare for Telehealth/Telemedicine Appointments, Including Technology and List of Questions - Questions for Our Panel of Experts

- Overview of CAR T-Cell Therapies - Understanding CARs – Chimeric Antigen Receptors - When to Consider CAR T-Cell Therapies as a Treatment Choice - Clinical Trials for CAR T-Cell Therapies - Discussion of CAR T-Cell Therapies - Managing Potential Treatment Side Effects - Specific Examples of How CAR T-Cell Therapies Contribute to Oncology Care - Key Questions to Ask Your Health Care Team about CAR T-Cell Therapies - The Benefits of CAR T-Cell Therapies - Follow-Up Care: What to Expect - Guidelines to Prepare for Telehealth/Telemedicine Appointments, Including Technology and List of Questions - Questions for Our Panel of Experts

- Overview of CAR T-Cell Therapies - Understanding CARs – Chimeric Antigen Receptors - When to Consider CAR T-Cell Therapies as a Treatment Choice - Clinical Trials for CAR T-Cell Therapies - Discussion of CAR T-Cell Therapies - Managing Potential Treatment Side Effects - Specific Examples of How CAR T-Cell Therapies Contribute to Oncology Care - Key Questions to Ask Your Health Care Team about CAR T-Cell Therapies - The Benefits of CAR T-Cell Therapies - Follow-Up Care: What to Expect - Guidelines to Prepare for Telehealth/Telemedicine Appointments, Including Technology and List of Questions - Questions for Our Panel of Experts

- Overview of CAR T-Cell Therapies - Understanding CARs – Chimeric Antigen Receptors - When to Consider CAR T-Cell Therapies as a Treatment Choice - Clinical Trials for CAR T-Cell Therapies - Discussion of CAR T-Cell Therapies - Managing Potential Treatment Side Effects - Specific Examples of How CAR T-Cell Therapies Contribute to Oncology Care - Key Questions to Ask Your Health Care Team about CAR T-Cell Therapies - The Benefits of CAR T-Cell Therapies - Follow-Up Care: What to Expect - Guidelines to Prepare for Telehealth/Telemedicine Appointments, Including Technology and List of Questions - Questions for Our Panel of Experts

- Overview of CAR T-Cell Therapies - Understanding CARs – Chimeric Antigen Receptors - When to Consider CAR T-Cell Therapies as a Treatment Choice - Clinical Trials for CAR T-Cell Therapies - Discussion of CAR T-Cell Therapies - Managing Potential Treatment Side Effects - Specific Examples of How CAR T-Cell Therapies Contribute to Oncology Care - Key Questions to Ask Your Health Care Team about CAR T-Cell Therapies - The Benefits of CAR T-Cell Therapies - Follow-Up Care: What to Expect - Guidelines to Prepare for Telehealth/Telemedicine Appointments, Including Technology and List of Questions - Questions for Our Panel of Experts

- Overview of CAR T-Cell Therapies - Understanding CARs – Chimeric Antigen Receptors - When to Consider CAR T-Cell Therapies as a Treatment Choice - Clinical Trials for CAR T-Cell Therapies - Discussion of CAR T-Cell Therapies - Managing Potential Treatment Side Effects - Specific Examples of How CAR T-Cell Therapies Contribute to Oncology Care - Key Questions to Ask Your Health Care Team about CAR T-Cell Therapies - The Benefits of CAR T-Cell Therapies - Follow-Up Care: What to Expect - Guidelines to Prepare for Telehealth/Telemedicine Appointments, Including Technology and List of Questions - Questions for Our Panel of Experts

- Overview of CAR T-Cell Therapies - Understanding CARs – Chimeric Antigen Receptors - When to Consider CAR T-Cell Therapies as a Treatment Choice - Clinical Trials for CAR T-Cell Therapies - Discussion of CAR T-Cell Therapies - Managing Potential Treatment Side Effects - Specific Examples of How CAR T-Cell Therapies Contribute to Oncology Care - Key Questions to Ask Your Health Care Team about CAR T-Cell Therapies - The Benefits of CAR T-Cell Therapies - Follow-Up Care: What to Expect - Guidelines to Prepare for Telehealth/Telemedicine Appointments, Including Technology and List of Questions - Questions for Our Panel of Experts

- Overview of CAR T-Cell Therapies - Understanding CARs – Chimeric Antigen Receptors - When to Consider CAR T-Cell Therapies as a Treatment Choice - Clinical Trials for CAR T-Cell Therapies - Discussion of CAR T-Cell Therapies - Managing Potential Treatment Side Effects - Specific Examples of How CAR T-Cell Therapies Contribute to Oncology Care - Key Questions to Ask Your Health Care Team about CAR T-Cell Therapies - The Benefits of CAR T-Cell Therapies - Follow-Up Care: What to Expect - Guidelines to Prepare for Telehealth/Telemedicine Appointments, Including Technology and List of Questions - Questions for Our Panel of Experts

- Overview of CAR T-Cell Therapies - Understanding CARs – Chimeric Antigen Receptors - When to Consider CAR T-Cell Therapies as a Treatment Choice - Clinical Trials for CAR T-Cell Therapies - Discussion of CAR T-Cell Therapies - Managing Potential Treatment Side Effects - Specific Examples of How CAR T-Cell Therapies Contribute to Oncology Care - Key Questions to Ask Your Health Care Team about CAR T-Cell Therapies - The Benefits of CAR T-Cell Therapies - Follow-Up Care: What to Expect - Guidelines to Prepare for Telehealth/Telemedicine Appointments, Including Technology and List of Questions - Questions for Our Panel of Experts

Andy Scharenberg, CEO of Seattle-based Umoja Biopharma, on developing in vivo CAR-T cell therapies.

In this week's episode we'll learn more about azacitidine-venetoclax combination therapy for first-line treatment of high-risk myelodysplastic syndromes; a new risk-scoring system for post-CAR T-cell hematotoxicity in B-cell acute lymphoblastic leukemia, also known as B-ALL; and a novel mechanism for inotuzumab ozogamicin resistance in B-ALL.Featured Articles:Efficacy and safety of venetoclax plus azacitidine for patients with treatment-naive high-risk myelodysplastic syndromesDevelopment of ALL-Hematotox: predicting post-CAR T-cell hematotoxicity in B-cell acute lymphoblastic leukemiaDNTT-mediated DNA damage response drives inotuzumab ozogamicin resistance in B-cell acute lymphoblastic leukemia

Send us a textBone Marrow Transplant (BMT) and CAR T-cell therapy are evolving fast—are you keeping up? In this episode of TheOncoPT Podcast, Dr. Adam Matichak returns to share the latest updates on these groundbreaking treatments and what they mean for your OncoPT practice.You'll learn how CAR T-cell therapy is expanding, why mobility strategies matter more than ever, and how to use vital signs to guide your treatment decisions. Plus, we'll explore how you can advocate for rehab's role in oncology, prepare patients for complex treatments like BMT and CAR T, and find the resources you need to stay ahead in this rapidly changing field.Whether you're new to cancer rehab or a seasoned pro, this conversation will give you practical tools to treat your patients undergoing BMT and/or CAR T-cell therapy. Listen now!Listen to Adam's previous episodes:Ep. 204 - How to not feel lost with BMTsEp. 221 - Here's How to Treat Patients Undergoing CAR T-Cell TherapyGrab your free Ultimate Oncology Specialist Study Guide!Preparing for the ABPTS Oncology Specialist Certification Exam is one of the best ways to become an expert OncoPT.My new Ultimate Oncology Specialist Study Guide will help you start your exam prep on the right foot, so you can prepare for success & treat your patients like an expert.Grab your FREE study guide now! Follow TheOncoPT on Instagram.Follow TheOncoPT on LinkedIn.

Featuring perspectives from Dr Jeremy S Abramson, Dr Jennifer Crombie, Prof Martin Hutchings, Dr Matthew Lunning and Dr Tycel Phillips, moderated by Dr Abramson, including the following topics: Introduction (0:00) Chimeric Antigen Receptor (CAR) T-Cell Therapy for Diffuse Large B-Cell Lymphoma (DLBCL) — Dr Abramson (2:17) Bispecific Antibody Therapy for DLBCL — Prof Hutchings (28:51) CAR T-Cell Therapy for Other Lymphoma Subtypes — Dr Lunning (52:01) Bispecific Antibody Therapy for Follicular Lymphoma and Other Lymphoma Subtypes — Dr Phillips (1:17:46) Tolerability Considerations with CAR T-Cell and Bispecific Antibody Therapy — Dr Crombie (1:41:44) CME information and select publications  

Dr Jennifer Crombie from Dana-Farber Cancer Institute, Prof Martin Hutchings from Copenhagen University Hospital, Dr Matthew Lunning from the University of Nebraska Medical Center, Dr Tycel Phillips from City of Hope and moderator Dr Jeremy S Abramson from Massachusetts General Hospital discuss recently updated data on the role of CAR T-cell therapy and bispecific antibodies in the management of diffuse large B-cell, mantle cell and follicular lymphoma.

Dr Jennifer Crombie from Dana-Farber Cancer Institute, Prof Martin Hutchings from Copenhagen University Hospital, Dr Matthew Lunning from the University of Nebraska Medical Center, Dr Tycel Phillips from City of Hope and moderator Dr Jeremy S Abramson from Massachusetts General Hospital discuss recently updated data on the role of CAR T-cell therapy and bispecific antibodies in the management of diffuse large B-cell, mantle cell and follicular lymphoma. Produced by Research To Practice. CME information and select publications here (https://www.researchtopractice.com/ASHCART24).

Imugene Ltd (ASX:IMU, OTC:IUGNF) managing director and CEO Leslie Chong joins Proactive's Tylah Tully to provide a company update, including launching the first Australian site for the Phase 1b clinical trial of its azer-cel (azercabtagene zapreleucel) allogeneic CAR T-cell therapy. The Royal Prince Alfred Hospital in Sydney will lead Australian patient recruitment, with enrolment beginning in November 2024, marking Australia's only active trial for allogeneic CAR T-cell therapy in treating relapsed or refractory diffuse large B-cell lymphoma (DLBCL). This Australian expansion offers patients access to azer-cel, addressing critical treatment gaps for DLBCL, an aggressive form of non-Hodgkin's lymphoma. Chong emphasised the importance of local access to this innovative therapy. Imugene's US trials have shown promising results, with three patients achieving complete responses, two of whom received a combination of azer-cel with lymphodepletion and interleukin-2 (IL-2), showing durable responses extending beyond 90 and 120 days. The company has also dosed the first patient in the intratumoural (IT) injection combination arm of its OASIS Phase 1 clinical trial for onCARlytics (CF33-CD19). This trial aims to test the efficacy and safety of Imugene's CD19-expressing oncolytic virotherapy in advanced or metastatic solid tumours. The first colorectal cancer patient was treated at Northwestern University, and the trial is expected to enrol up to 40 participants with various advanced cancers. #ProactiveInvestors #Imugene #ASX  #Oncology #CAR_TCellTherapy #AzerCel #Vaxinia #ClinicalTrials #CancerResearch #Immunotherapy #DLBCL #HER2 #BileCancer #Biotechnology #ASX #FDAApproval #OrphanDrug #FastTrack #BiotechInvesting #OncolyticVirotherapy #CancerTreatment #CashPosition

- Overview of CAR T-Cell Therapies - Understanding CARs – Chimeric Antigen Receptors - When to Consider CAR T-Cell Therapies as a Treatment Choice - Clinical Trials for CAR T-Cell Therapies - Discussion of CAR T-Cell Therapies - Managing Potential Treatment Side Effects - Specific Examples of How CAR T-Cell Therapies Contributes to Oncology Care - Key Questions to Ask Your Health Care Team about CAR T-Cell Therapies - The Benefits of CAR T-Cell Therapies - Follow-Up Care: What to Expect - Guidelines to Prepare for Telehealth/Telemedicine Appointments, Including Technology, Prepared List of Questions & Quality-of-Life Concerns - Questions for Our Panel of Experts

- Overview of CAR T-Cell Therapies - Understanding CARs – Chimeric Antigen Receptors - When to Consider CAR T-Cell Therapies as a Treatment Choice - Clinical Trials for CAR T-Cell Therapies - Discussion of CAR T-Cell Therapies - Managing Potential Treatment Side Effects - Specific Examples of How CAR T-Cell Therapies Contributes to Oncology Care - Key Questions to Ask Your Health Care Team about CAR T-Cell Therapies - The Benefits of CAR T-Cell Therapies - Follow-Up Care: What to Expect - Guidelines to Prepare for Telehealth/Telemedicine Appointments, Including Technology, Prepared List of Questions & Quality-of-Life Concerns - Questions for Our Panel of Experts

- Overview of CAR T-Cell Therapies - Understanding CARs – Chimeric Antigen Receptors - When to Consider CAR T-Cell Therapies as a Treatment Choice - Clinical Trials for CAR T-Cell Therapies - Discussion of CAR T-Cell Therapies - Managing Potential Treatment Side Effects - Specific Examples of How CAR T-Cell Therapies Contributes to Oncology Care - Key Questions to Ask Your Health Care Team about CAR T-Cell Therapies - The Benefits of CAR T-Cell Therapies - Follow-Up Care: What to Expect - Guidelines to Prepare for Telehealth/Telemedicine Appointments, Including Technology, Prepared List of Questions & Quality-of-Life Concerns - Questions for Our Panel of Experts

- Overview of CAR T-Cell Therapies - Understanding CARs – Chimeric Antigen Receptors - When to Consider CAR T-Cell Therapies as a Treatment Choice - Clinical Trials for CAR T-Cell Therapies - Discussion of CAR T-Cell Therapies - Managing Potential Treatment Side Effects - Specific Examples of How CAR T-Cell Therapies Contributes to Oncology Care - Key Questions to Ask Your Health Care Team about CAR T-Cell Therapies - The Benefits of CAR T-Cell Therapies - Follow-Up Care: What to Expect - Guidelines to Prepare for Telehealth/Telemedicine Appointments, Including Technology, Prepared List of Questions & Quality-of-Life Concerns - Questions for Our Panel of Experts

- Overview of CAR T-Cell Therapies - Understanding CARs – Chimeric Antigen Receptors - When to Consider CAR T-Cell Therapies as a Treatment Choice - Clinical Trials for CAR T-Cell Therapies - Discussion of CAR T-Cell Therapies - Managing Potential Treatment Side Effects - Specific Examples of How CAR T-Cell Therapies Contributes to Oncology Care - Key Questions to Ask Your Health Care Team about CAR T-Cell Therapies - The Benefits of CAR T-Cell Therapies - Follow-Up Care: What to Expect - Guidelines to Prepare for Telehealth/Telemedicine Appointments, Including Technology, Prepared List of Questions & Quality-of-Life Concerns - Questions for Our Panel of Experts

- Overview of CAR T-Cell Therapies - Understanding CARs – Chimeric Antigen Receptors - When to Consider CAR T-Cell Therapies as a Treatment Choice - Clinical Trials for CAR T-Cell Therapies - Discussion of CAR T-Cell Therapies - Managing Potential Treatment Side Effects - Specific Examples of How CAR T-Cell Therapies Contributes to Oncology Care - Key Questions to Ask Your Health Care Team about CAR T-Cell Therapies - The Benefits of CAR T-Cell Therapies - Follow-Up Care: What to Expect - Guidelines to Prepare for Telehealth/Telemedicine Appointments, Including Technology, Prepared List of Questions & Quality-of-Life Concerns - Questions for Our Panel of Experts

- Overview of CAR T-Cell Therapies - Understanding CARs – Chimeric Antigen Receptors - When to Consider CAR T-Cell Therapies as a Treatment Choice - Clinical Trials for CAR T-Cell Therapies - Discussion of CAR T-Cell Therapies - Managing Potential Treatment Side Effects - Specific Examples of How CAR T-Cell Therapies Contributes to Oncology Care - Key Questions to Ask Your Health Care Team about CAR T-Cell Therapies - The Benefits of CAR T-Cell Therapies - Follow-Up Care: What to Expect - Guidelines to Prepare for Telehealth/Telemedicine Appointments, Including Technology, Prepared List of Questions & Quality-of-Life Concerns - Questions for Our Panel of Experts

- Overview of CAR T-Cell Therapies - Understanding CARs – Chimeric Antigen Receptors - When to Consider CAR T-Cell Therapies as a Treatment Choice - Clinical Trials for CAR T-Cell Therapies - Discussion of CAR T-Cell Therapies - Managing Potential Treatment Side Effects - Specific Examples of How CAR T-Cell Therapies Contributes to Oncology Care - Key Questions to Ask Your Health Care Team about CAR T-Cell Therapies - The Benefits of CAR T-Cell Therapies - Follow-Up Care: What to Expect - Guidelines to Prepare for Telehealth/Telemedicine Appointments, Including Technology, Prepared List of Questions & Quality-of-Life Concerns - Questions for Our Panel of Experts

- Overview of CAR T-Cell Therapies - Understanding CARs – Chimeric Antigen Receptors - When to Consider CAR T-Cell Therapies as a Treatment Choice - Clinical Trials for CAR T-Cell Therapies - Discussion of CAR T-Cell Therapies - Managing Potential Treatment Side Effects - Specific Examples of How CAR T-Cell Therapies Contributes to Oncology Care - Key Questions to Ask Your Health Care Team about CAR T-Cell Therapies - The Benefits of CAR T-Cell Therapies - Follow-Up Care: What to Expect - Guidelines to Prepare for Telehealth/Telemedicine Appointments, Including Technology, Prepared List of Questions & Quality-of-Life Concerns - Questions for Our Panel of Experts

- Overview of CAR T-Cell Therapies - Understanding CARs – Chimeric Antigen Receptors - When to Consider CAR T-Cell Therapies as a Treatment Choice - Clinical Trials for CAR T-Cell Therapies - Discussion of CAR T-Cell Therapies - Managing Potential Treatment Side Effects - Specific Examples of How CAR T-Cell Therapies Contributes to Oncology Care - Key Questions to Ask Your Health Care Team about CAR T-Cell Therapies - The Benefits of CAR T-Cell Therapies - Follow-Up Care: What to Expect - Guidelines to Prepare for Telehealth/Telemedicine Appointments, Including Technology, Prepared List of Questions & Quality-of-Life Concerns - Questions for Our Panel of Experts

- Overview of CAR T-Cell Therapies - Understanding CARs – Chimeric Antigen Receptors - When to Consider CAR T-Cell Therapies as a Treatment Choice - Clinical Trials for CAR T-Cell Therapies - Discussion of CAR T-Cell Therapies - Managing Potential Treatment Side Effects - Specific Examples of How CAR T-Cell Therapies Contributes to Oncology Care - Key Questions to Ask Your Health Care Team about CAR T-Cell Therapies - The Benefits of CAR T-Cell Therapies - Follow-Up Care: What to Expect - Guidelines to Prepare for Telehealth/Telemedicine Appointments, Including Technology, Prepared List of Questions & Quality-of-Life Concerns - Questions for Our Panel of Experts

- Overview of CAR T-Cell Therapies - Understanding CARs – Chimeric Antigen Receptors - When to Consider CAR T-Cell Therapies as a Treatment Choice - Clinical Trials for CAR T-Cell Therapies - Discussion of CAR T-Cell Therapies - Managing Potential Treatment Side Effects - Specific Examples of How CAR T-Cell Therapies Contributes to Oncology Care - Key Questions to Ask Your Health Care Team about CAR T-Cell Therapies - The Benefits of CAR T-Cell Therapies - Follow-Up Care: What to Expect - Guidelines to Prepare for Telehealth/Telemedicine Appointments, Including Technology, Prepared List of Questions & Quality-of-Life Concerns - Questions for Our Panel of Experts

In this week's episode we'll discuss the outcomes of younger patients with mantle cell lymphoma experiencing late relapse; learn more about mass spectrometry-based assessment of M-protein in peripheral blood during maintenance therapy in multiple myeloma and discuss in vivo CAR T-cell generation in non-human primates using lentiviral vectors.Featured Articles: Outcomes of younger patients with mantle cell lymphoma experiencing late relapse (>24 months): the LATE-POD studyMass spectrometry–based assessment of M protein in peripheral blood during maintenance therapy inmultiple myelomaIn vivo CAR T-cell generation in nonhuman primates using lentiviral vectors displaying a multidomain fusion ligand

In this week's episode we'll learn about iron, HFE hemochromatosis, and infections. In this large, population-based study, both high and low levels of plasma iron and transferrin saturation were associated with increased risks of infection. Then, we'll discuss how bispecific antibodies improve CAR T-cell response in B-cell malignancies. In-vitro and in-vivo data demonstrate enhanced therapeutic efficacy when a CD20-directed bispecific antibody is given in combination with CD19-directed CAR-T cells. Finally, we'll hear about determinants of outcome in NPM1-mutated AML. In a large series of patients with NPM1-mutated AML, investigators identified several variables beyond FLT3-ITD that adversely impacted outcomes. Featured Articles:Iron, hemochromatosis genotypes, and risk of infections: a cohort study of 142 188 general population individualsMolecular, clinical, and therapeutic determinants of outcome in NPM1-mutated AMLCD20-bispecific antibodies improve response to CD19-CAR T cells in lymphoma in vitro and CLL in vivo models

Kamala Harris afirma ter delegados suficientes para ser nomeada candidata à Presidência e se diz 'honrada'. Boi com chip na Amazônia: como funciona o rastreamento para saber se a carne está livre de desmatamento. Site usa foto de paciente de Car-T Cell para vender 'pílula do câncer'; fosfoetanolamina não tem eficácia comprovada, afirma Anvisa. Pesquisa encontra cocaína em tubarões no Rio de Janeiro. Além de escolher prefeitos, algumas cidades vão decidir sobre troca de bandeira, passe livre e outros temas locais; entenda.

Sixty patients with the rare non-Hodgkin Lymphoma blood cancer, will be given CAR-T Cell therapy which reprogrammes their immune cells to recognise and kill cancer cells. Cancer patient David Down spoke to Ingrid Hipkiss.

In this week's episode we'll discuss new insights on the role of GM-CSF in establishing immune memory. The authors propose that the coordination of opposing immune memory programs, driven by GM-CSF, may be essential to efficient, yet controlled, innate immune responses. After that: Interleukin-1 inhibition in TTP. Researchers explore the potential of recombinant IL-1 receptor antagonist, anakinra, in a murine model of thrombotic thrombocytopenic purpura—an uncommon but potentially fatal disorder with limited therapeutic options. Finally, we'll learn about CAR T-cell therapy outcomes by race and ethnicity in large B-cell lymphoma. Non-Hispanic Black patients had lower rates of response and progression-free survival in axi-cel clinical trials and real-world data, raising awareness and giving further insights into potential inequitable access to care.Featured Articles:GM-CSF receptor expression determines opposing innate memory phenotypes at different stages of myelopoiesis Mortality, cardiac and cerebral damage reduction by IL-1 inhibition in a murine model of TTP Real-World and Clinical Trial Outcomes in Large B-cell Lymphoma with Axicabtagene Ciloleucel Across Race and Ethnicity 

By now, you likely have heard about CAR-T Cell therapy, but what exactly is it? Today, we dive headlong into this topic with Dr. Max Konig. We cover how this therapy works, how CAR-T Cells are made and administered to patients. We discuss the risks associated with this type of therapy, the side effects and their management. Lastly, we'll discuss the rheumatic diseases amenable to CAR-T therapy, those that are not, the costs and ethics involved and what the future may hold for it in rheumatology. Enjoy! 

As the use of chimeric antigen receptor (CAR) T-cell therapy continues to expand as an effective treatment for hematologic malignancies, understanding how to identify eligible patients early and implementation of an effective framework for identification can improve care coordination and better prepare community cancer programs for widespread use of CAR T-cell therapy. In this episode, CANCER BUZZ speaks with David L. Porter, MD, director of Cell Therapy and Transplant at Penn Medicine, about the challenges community oncologists face and the key role they can play in identifying and recommending eligible patients for CAR T-cell therapy.   “The single most important thing for a patient out in the community at a place that doesn't have familiarity or immediate access to CAR T-cells is to refer them somewhere that does and refer them soon and timely.” – David L. Porter, MD   Guest:  David L. Porter, MD Director, Cell Therapy and Transplant Jodi Fisher Horowitz Professor in Leukemia Care Excellence Penn Medicine- University of Pennsylvania Health System (UPHS) Philadelphia, PA   This episode has been developed in connection with the ACCC education program Tips for Early Patient Identification for CAR T-Cell Therapy and Creating “Stickiness” with Community Providers for Optimal Care Coordination. This episode was made possible with support by Kite Pharma.   Additional Reading/Sources ACCC Oncology Issues Article If They RECUR, You Should Refer: A Community Oncologist Patient ID Roundtable Summary Essentials for Identifying Patients – Bringing CAR T-cell Therapy to Community Oncology Optimizing Care Coordination – Bringing CAR T-cell Therapy to Community Oncology

In this episode, Carl June, MD, pioneering immunologist and oncologist at the University of Pennsylvania, joins Jorge Conde, general partner at a16z Bio + Health.Together, they discuss Carl's work on CAR T, a remarkable story of the first use of CAR T in a pediatric patient, and Carl's take on where oncology treatments are headed next.Though this episode was originally published in September 2023, back when we were called Bio Eats World, we're republishing it  during this year's ASGCT conference, where the latest advances in cell and gene therapy—like what Carl describes—are shared and discussed.

Neste episódio, Renata Capucci e Maria Scodeler recebem o doutor Vanderson Rocha, professor da USP, e Paulo Peregrino, publicitário em remissão do câncer graças ao tratamento Car-T Cell. Eles falam sobre a terapia promissora que já começou a dar resultados no Brasil.

CAR-T cells, used to treat cancer in some people, are now being investigated by the US Food and Drug Administration for possibly causing additional cancers. Kimmel Cancer Center director William Nelson at Johns Hopkins explains why there's a concern. Nelson: … Why are CAR-T cell therapies being investigated by the FDA? Elizabeth Tracey reports Read More »

The fellas are joined again by Dr. Brian Koffman, a well-known doctor, educator, and clinical professor turned patient has dedicated himself to teaching and helping the Chronic Lymphocytic Leukemia (CLL) community since his diagnosis in 2005. Dr. Koffman believes that his dual status as a physician and patient provides a unique experience and understanding which allows him to provide clear explanations of complex issues and to advocate for his fellow patients and inform his fellow healthcare providers. This week Dr. Koffman joins the boys to chat about CAR-T Cell therapy and all the things you'd ever want to know about drug trials! Join the post-episode conversation over on Discord! https://discord.gg/expeUDN

The fellas are joined again by Dr. Brian Koffman, a well-known doctor, educator, and clinical professor turned patient has dedicated himself to teaching and helping the Chronic Lymphocytic Leukemia (CLL) community since his diagnosis in 2005. Dr. Koffman believes that his dual status as a physician and patient provides a unique experience and understanding which allows him to provide clear explanations of complex issues and to advocate for his fellow patients and inform his fellow healthcare providers. This week Dr. Koffman joins the boys to chat about CAR-T Cell therapy and all the things you'd ever want to know about drug trials! Join the post-episode conversation over on Discord! https://discord.gg/expeUDN

As the use of chimeric antigen receptor (CAR) T-cell therapy continues to expand as an effective treatment for hematologic malignancies, understanding how to identify eligible patients early and implementation of an effective framework for identification can improve care coordination and better prepare community cancer programs for widespread use of CAR T-cell therapy. In this episode, CANCER BUZZ speaks with David L. Porter, MD, director of Cell Therapy and Transplant at Penn Medicine, about the challenges community oncologists face and the key role they can play in identifying and recommending eligible patients for CAR T-cell therapy.   “The single most important thing for a patient out in the community at a place that doesn't have familiarity or immediate access to CAR T-cells is to refer them somewhere that does and refer them soon and timely.” – David L. Porter, MD   Guest:  David L. Porter, MD Director, Cell Therapy and Transplant Jodi Fisher Horowitz Professor in Leukemia Care Excellence Penn Medicine- University of Pennsylvania Health System (UPHS) Philadelphia, PA   This episode has been developed in connection with the ACCC education program Tips for Early Patient Identification for CAR T-Cell Therapy and Creating “Stickiness” with Community Providers for Optimal Care Coordination. This episode was made possible with support by Kite Pharma.   Additional Reading/Sources If They RECUR, You Should Refer: A Community Oncologist Patient ID Roundtable Summary Essentials for Identifying Patients – Bringing CAR T-cell Therapy to Community Oncology Optimizing Care Coordination – Bringing CAR T-cell Therapy to Community Oncology

Safety alert issued for serious reactions to certain seizure drugs; Drug approved to treat a rare form of tumor; T-cell malignancies reported with cell immunotherapies; organ transplant rejection treatment recalled; CPAP machine associated with reports of burns and fires.

In 2019 the Wellington based Malaghan Institute of Medical Research began trialing a ground breaking treatment, a locally developed CAR T-Cell therapy. Author and comedian David Downs is an ambassador for the trial.

In this week's episode, we'll learn that Germline pathogenic variants of the DDX41 gene are relatively common in the general population and linked to higher risk of AML and MDS, discuss the birtamimab plus standard of care in light chain amyloidosis, and review new insights on rare movement and neurocognitive toxicities that are observed after BCMA-directed CAR T cell treatment. 

Umoja Biopharma's CEO, Andy Scharenberg, M.D., joins Cell & Gene: The Podcast's Erin Harris to discuss the evolution of allogeneic, in vivo CAR-T cell therapeutics. They discuss The Climb, or The Colorado Laboratory and Innovation Manufacturing Building, which is Umoja's lentiviral vector development and manufacturing facility. They also cover recent progress in lentiviral vector manufacturing.

Paulo Pelegrino tem 61 anos, e viveu os últimos 13 sob contínuos tratamentos para se livrar do câncer. Em 2023, conseguiu. Durante 1 mês, Paulo foi submetido a uma terapia experimental que está sendo desenvolvida e aplicada no Brasil pela USP, em parceria com o Instituto Butantan e o Hemocentro de Ribeirão Preto. Trata-se da CAR-T Cell, tecnologia celular aplicada em alguns pacientes na Europa e nos EUA - lá, o tratamento custa cerca de R$ 2 milhões; aqui, o SUS irá disponibilizá-la gratuitamente assim que for aprovada pela Anvisa. Paulo relata a Natuza Nery o que ele passou nos últimos anos. Participa também o médico Dimas Covas, diretor do Hemocentro de Ribeirão Preto, professor da USP na mesma cidade e coordenador do Centro de Terapia Celular da instituição. Neste episódio: - Paulo conta o que sentiu ao ver as imagens de seus exames antes e depois da terapia: a primeira mostra um corpo tomado por tumores, e a segunda “era como se tivessem passado uma borracha naquilo”. “A ficha não caiu ainda”, celebra; - Para Paulo, o desfecho de sua história é uma “ressureição”. Ele diz se sentir “envaidecido” de ter sido um dos 14 pacientes cobaia deste experimento, realizado gratuitamente pelo SUS e que devolve às pessoas “a crença na ciência e a esperança na cura”; - Dimas Covas explica o que é a terapia CAR-T Cell e descreve seu funcionamento: as células T do paciente são extraídas e, no laboratório, são modificadas geneticamente para perseguirem e atacarem as células cancerígenas. De volta ao corpo, ele afirma, “essas células conseguem em 15 a 20 dias destruírem completamente o tumor”; - Ele anuncia que “o próximo desafio é levar o tratamento aos pacientes do SUS”. Para isso, o primeiro passo é registrar a terapia na Anvisa e, depois, “em um prazo máximo de um ano e alguns meses” poderemos ver este tratamento disponibilizado no SUS. “O CAR-T Cell será a nova fronteira do tratamento de câncer em geral”, conclui.